Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $9.73

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have received a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.73.

Several research firms have issued reports on ALLO. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler dropped their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th.

Allogene Therapeutics Trading Up 1.6 %

Shares of ALLO opened at $1.87 on Wednesday. The stock has a market cap of $392.09 million, a PE ratio of -1.20 and a beta of 0.83. Allogene Therapeutics has a 1 year low of $1.78 and a 1 year high of $5.78. The stock has a 50 day simple moving average of $2.49 and a 200-day simple moving average of $2.57.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ALLO. The Manufacturers Life Insurance Company lifted its stake in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after purchasing an additional 5,642 shares during the period. Nisa Investment Advisors LLC increased its holdings in Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after purchasing an additional 8,734 shares during the last quarter. Arizona State Retirement System lifted its stake in Allogene Therapeutics by 36.1% in the second quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after buying an additional 10,855 shares during the period. Private Advisor Group LLC bought a new position in Allogene Therapeutics during the third quarter worth about $34,000. Finally, Federated Hermes Inc. bought a new position in Allogene Therapeutics during the second quarter worth about $29,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).